Comparative Pharmacology
Head-to-head clinical analysis: LAMPIT versus MEPRON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMPIT versus MEPRON.
LAMPIT vs MEPRON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the enzyme G6PD (glucose-6-phosphate dehydrogenase) in Trypanosoma cruzi, leading to oxidative stress and parasite death.
It is a hydroxynaphthoquinone that selectively inhibits mitochondrial electron transport chain in Plasmodium species, specifically at the cytochrome bc1 complex (Complex III), leading to collapse of mitochondrial membrane potential and inhibition of pyrimidine synthesis.
Nifurtimox (Lampit) for Chagas disease: adult dose 8-10 mg/kg/day orally in 3 divided doses for 90 days. For Chagas disease in children: 15-20 mg/kg/day orally in 3 divided doses for 90 days.
750 mg orally twice daily with food for 21 days for treatment of mild-to-moderate Pneumocystis jirovecii pneumonia. For prophylaxis: 1500 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours. In hepatic impairment, half-life may be prolonged by up to 2-fold.
Mean terminal elimination half-life is 2.2-3.2 days (approximately 53-77 hours) in adults; prolonged in hepatic impairment (up to 22 days) and in elderly (up to 5 days).
Renal excretion of unchanged drug accounts for 10% of the dose; biliary/fecal excretion accounts for approximately 90%, mainly as metabolites.
Primarily fecal (87-94%) via bile; renal excretion accounts for <1% as unchanged drug. A minor metabolite, atovaquone glucuronide, is excreted in urine.
Category C
Category C
Antiprotozoal
Antiprotozoal